Hepatitis B Vaccine Dosing and Administration
For healthy adults aged ≥20 years, administer 20 mcg (1.0 mL) of recombinant hepatitis B vaccine intramuscularly at 0,1, and 6 months, which achieves 96% seroprotection by month 7. 1
Standard Dosing by Age Group
The 2022 ACIP guidelines provide clear, age-stratified dosing recommendations 1:
Adolescents and Children
- Ages 11-19 years: 10 mcg (0.5 mL) at 0,1, and 6 months
- Ages 11-15 years (Recombivax HB only): Alternative 2-dose schedule of 10 mcg at 0 and 4-6 months
- Birth through 10 years: 10 mcg (0.5 mL) at 0,1, and 6 months
Adults
- Ages ≥20 years: 20 mcg (1.0 mL) at 0,1, and 6 months
- This achieves 79% seroprotection at month 6 and 96% at month 7, with a geometric mean titer (GMT) of 2,204 mIU/mL among seroconverters 2
Special Populations Requiring Higher Doses
Hemodialysis patients and immunocompromised adults (≥20 years):
- Engerix-B: 40 mcg (2.0 mL) at 0,1,2, and 6 months (4-dose series)
- Recombivax HB: 40 mcg (1.0 mL) at 0,1, and 6 months (3-dose series)
- Achieves only 67% seroprotection with 4-dose regimen, significantly lower than healthy adults 1, 2
Important caveat: Heplisav-B and PreHevbrio have not been established as safe or effective in hemodialysis patients and should not be used 1
Alternative Vaccine Options
Heplisav-B (Adults ≥18 years)
- Dose: 20 mcg (0.5 mL) at 0 and 1 month only
- Simplified 2-dose schedule improves compliance 1
PreHevbrio (Adults ≥18 years)
- Dose: 10 mcg (1.0 mL) at 0,1, and 6 months
- Three-antigen formulation, ACIP-recommended in 2022 1
Twinrix (HepA-HepB combination, Adults ≥18 years)
- Standard: 20 mcg HBsAg (1.0 mL) at 0,1, and 6 months
- Accelerated: 4 doses at 0 days, 7 days, 21-30 days, and 12 months for rapid protection 1
Accelerated Schedules for High-Risk Situations
When rapid protection is needed (recent exposure, neonates of HBsAg-positive mothers, imminent travel to endemic areas):
0,1,2,12-month schedule:
- Achieves 99% seroprotection by month 3
- Fourth dose at 12 months produces GMT of 9,163 mIU/mL, ensuring long-term protection 2
- Research supports this approach achieves earlier seroconversion than standard schedules 3, 4
Administration Technique
Route and site 2:
- Intramuscular injection only (never intravenous or intradermal)
- Adults: Deltoid muscle
- Infants and young children: Anterolateral thigh
- Never gluteal region: Results in suboptimal response
Needle selection:
- Infants <12 months: 1-inch, 23-gauge (anterolateral thigh)
- Children 1-10 years: 5/8-inch, 25-gauge (deltoid)
- Older children and adults: 1-inch, 23-gauge (deltoid)
Subcutaneous administration: Only for patients at hemorrhage risk (e.g., hemophiliacs), but expect lower GMTs and increased local reactions including nodules 2
Critical Timing Intervals
If schedule is interrupted 5:
- Never restart the series
- Minimum interval between doses 1 and 2: 4 weeks
- Minimum interval between doses 2 and 3: 8 weeks
- Minimum interval between doses 1 and 3: 16 weeks
- Doses given ≤4 days before minimum interval are valid
Exception: The 4-day grace period does NOT apply to Twinrix accelerated schedule (0,7,21-30 days, 12 months) 5
Special Considerations
Pregnancy
Use only Engerix-B, Recombivax HB, or Twinrix—insufficient safety data for Heplisav-B and PreHevbrio 1
Older Adults (>40 years)
Expect lower antibody responses (GMT 610 mIU/mL vs. higher in younger adults), but 88% still achieve seroprotection 2
Vaccine Interchangeability
Different manufacturers' products can be used to complete a series without repeating doses, though same brand is preferable when feasible 5
Post-Vaccination Testing
Required for specific high-risk groups 1-2 months after final dose 5:
- Infants born to HBsAg-positive mothers
- Healthcare personnel and public safety workers
- Hemodialysis patients
- HIV-infected and other immunocompromised persons
Target: Anti-HBs ≥10 mIU/mL indicates seroprotection
Non-Responders
Healthcare personnel with anti-HBs <10 mIU/mL after complete series should receive one additional dose, retest in 1-2 months, and if still <10 mIU/mL, complete a second full series (total 6 doses) 5
Common Pitfalls to Avoid
- Don't delay vaccination for serologic testing: Test and vaccinate simultaneously in high-risk populations 1
- Don't use gluteal injection: Consistently produces suboptimal responses 2
- Don't restart interrupted series: Simply continue with appropriate intervals 5
- Don't use Heplisav-B or PreHevbrio in dialysis patients or pregnant women: Insufficient safety/efficacy data 1
- Don't forget the 4th dose in accelerated schedules: The 12-month booster is essential for long-term protection 2